Dr. David S. Saperstein, MD
Neurology (Neurology Physician)
7054 E. Cochise Road, Ste B230
Scottsdale, AZ 85253
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
Medicare and federal program status
Opted out of Medicare from October 28, 2021 through October 28, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated November 14, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 34039
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Privigen (immun glob g(igg)/pro/iga 0-50) | 86 |
| Gammaplex (immun glob g(igg)/gly/iga 0-50) | 84 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Scottsdale, AZ | 70 |
| Diphenhydramine Hcl | 55 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 51 |
| Gabapentin Other prescribers in Scottsdale, AZ | 44 |
| Pregabalin Other prescribers in Scottsdale, AZ | 42 |
| Ondansetron Hcl (ondansetron hcl/pf) | 32 |
| Lactated Ringers (ringer's solution,lactated) | 30 |
| Promethazine Hcl Other prescribers in Scottsdale, AZ | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 25 payments worth $669 in total to this clinician.
| UCB, Inc. | $141 |
|---|---|
| AbbVie Inc. | $86.28 |
| Csl Behring | $78.56 |
| Pfizer Inc. | $74.06 |
| Argenx US, Inc. | $63.41 |
| Alexion Pharmaceuticals, Inc. | $53.94 |
| Lundbeck LLC | $29.63 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.22 |
| Food and Beverage | $669 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $24,610 in research payments for these studies, mostly to the institutions running them.
- Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
Csl Behring · Terminated · NCT06524739
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.